AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 11 min read$CRNX

WIERENGA WENDELL sold (to issuer) $10.4M of CRNX

WIERENGA WENDELL sold (to issuer) 122,071 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($10.38M total) across 2 trades on 2026-09-01.

Original reporting
SEC EDGAR · WIERENGA WENDELL
Published Sep 1, 2026, 9:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CRNX
Bearish
medium confidence
Mentioned
$CRNX
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRNXBearishLow
01

Why it matters

The director's sale reduces insider ownership to zero, potentially affecting market perception.

02

Market read

Insider sell of $10M may influence CRNX price action in the short term.

03

What to watch

No 10b5‑1 plan; sale may be unrelated to company fundamentals.

Relevance 7/10Novelty 5/10Timing: 2026-09-01 filing

Background

SEC Form 4 disclosures provide primary source data on insider transactions.

Company-level read

Ticker impact

$CRNXBearishMedium confidence
Context

Director Wierenga Wendell sold 122,071 shares for $10.4M in a Form 4 filing.

Expected impact

Possible short-term downside pressure.

Evidence & confidence

A $10M sale by a director is material for a micro‑cap biotech and could trigger sell‑offs.

Market effects

Sector

May raise concerns for other small‑cap biotech insiders.

Regional

Limited to US biotech investors.

Global

Low

Counterpoint

What could challenge this read

Insider sell could be routine liquidity event, not a red flag.

Key entities

  • Company
    Crinetics Pharmaceuticals, Inc.

    NASDAQ‑listed biotech (CRNX).

  • Individual
    Wierenga Wendell

    Director of Crinetics who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRNX insider trading history →

Related articles

SEP 2
$VRTXHighAI 9/10

Vertex Completes $10 Billion Acquisition Of Crinetics Pharmaceuticals

Vertex Pharmaceuticals completed its $10 billion acquisition of Crinetics Pharmaceuticals, adding PALSONIFY and atumelnant to its portfolio. The deal, closed on September 1, 2026, is expected to boost revenue growth and become accretive to non-GAAP operating income by 2029. Vertex also announced leadership changes, including a new CFO.

pulse2.com2 min
SEP 2
$CRNXLowAI 9/10

What Does Crinetics Pharmaceuticals (CRNX) Delisting Mean After The Takeover Closed?

Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals (CRNX), delisting it from Nasdaq. Crinetics is now a subsidiary, with leadership changes announced. The $10B deal was funded by cash, debt, and $4.5B in bridge financing. Vertex gains exposure to Crinetics' endocrine disease treatments. Investors should watch for updates on pipeline and commercial priorities.

simplywall.st2 min
SEP 1
$VRTXHighAI 9/10

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

Vertex Pharmaceuticals (VRTX) completed its $10B acquisition of Crinetics Pharmaceuticals (CRNX) on September 1, 2026. The deal adds PALSONIFY and atumelnant to Vertex's pipeline, with potential peak revenue of $5B. Vertex also announced leadership changes, including Jonathan Poole's appointment as EVP, CFO in 2027 and Jasper van Grunsven joining as EVP, Chief Pain and New Product Planning Officer.

investingnews.com2 min